Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
The Oncologist · 02.11.2023 · 28 (11) · e981-e994
DOI: 10.1093/oncolo/oyad138 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, online erschienen am 11.07.2023. Verfasst von John H Strickler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Duke University Medical Center, Durham, NC, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen Inc.
Abstract (Originalsprache)
Purpose
A systematic literature review was conducted to estimate the global prevalence of Kirsten rat sarcoma virus gene (KRAS) mutations, with an emphasis on the clinically significant KRAS G12C mutation, and to estimate the prognostic significance of these mutations in patients with colorectal cancer (CRC).
Design
Relevant English-language publications in the Embase, MEDLINE, and the Cochrane Library databases (from 2009 to 2021) and congress presentations (from 2016 to 2021) were reviewed. Eligible studies were those that reported the prevalence and clinical outcomes of the KRAS G12C mutation in patients with CRC.
Results
A total of 137 studies (interventional [n = 8], post hoc analyses of randomized clinical trials [n = 6], observational [n = 122], and longitudinal [n =1]) were reviewed. Sixty-eight studies reported the prevalence of KRAS mutations (KRASm) in 42 810 patients with CRC. The median global prevalence of KRASm was 38% (range, 13.3%-58.9%) and that of the KRAS G12C mutation (KRAS G12C) 3.1% (range, 0.7%-14%). Available evidence suggests that KRASm are possibly more common in tumors that develop on the right side of the colon. Limited evidence suggests a lower objective response rate and inferior disease-free/relapse-free survival in patients with KRAS G12C compared with patients with KRASwt or other KRASm.
Conclusion
Our analysis reveals that KRAS G12C is prevalent in 3% of patients with CRC. Available evidence suggests a poor prognosis for patients with KRAS G12C. Right-sided tumors were more likely to harbor KRASm; however, their role in determining clinical outcomes needs to be investigated further.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Duke University Medical Center, Durham, NC, USA.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Health Economics and Outcomes Researc, Amgen Inc., Thousand Oaks, CA, USA.
- Value Demonstration Practice, Oxford Pharmagenesis, Oxford, UK.
- Health Economics and Outcomes Research, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
- Global Medical Affairs, Amgen Inc., Thousand Oaks, CA, USA.
ORCID-Profile: Takayuki Yoshino, Dominik Paul Modest
Förderung
- Amgen Inc
Zitieren
APA
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023). Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. The Oncologist, 28(11), e981-e994. https://doi.org/10.1093/oncolo/oyad138
Vancouver
Strickler JH, Yoshino T, Stevinson K, Eichinger CS, Giannopoulou C, Rehn M, et al. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. The Oncologist. 2023;28(11):e981-e994. doi:10.1093/oncolo/oyad138
BibTeX
@article{Strickler2023,
author = {Strickler, John H and Yoshino, Takayuki and Stevinson, Kendall and Eichinger, Christian Stefan and Giannopoulou, Christina and Rehn, Marko and Modest, Dominik Paul},
title = {Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {11},
pages = {e981--e994},
doi = {10.1093/oncolo/oyad138}
}
EUVIMED